SOURCE: Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.

February 18, 2015 07:30 ET

Cleveland BioLabs Announces Receipt of Letter From NASDAQ Confirming Compliance With Minimum Bid Price Requirement

BUFFALO, NY--(Marketwired - Feb 18, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on February 12, 2015, the Company received a letter from The NASDAQ Stock Market stating that the Company has regained compliance with Listing Rule 5550(a)(2), maintenance of a minimum bid price of $1.00.

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are entolimod, which is being developed for a biodefense indication and as a potential cancer treatment, and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through two operating subsidiaries, BioLabs 612, LLC and Panacela Labs, Inc. and an equity investee, Incuron, LLC. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.

Contact Information

  • Contact:
    Rachel Levine
    Vice President Investor Relations
    Cleveland BioLabs, Inc.
    T: (917) 375-2935
    E: rlevine@cbiolabs.com